Michael W. Kalb - 05 Jan 2026 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Executive Vice President & CFO
Signature
/s/ Michael W. Kalb
Issuer symbol
CPRX
Transactions as of
05 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 17:00:47 UTC
Previous filing
24 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kalb Michael Wayne Executive Vice President & CFO 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Michael W. Kalb 06 Jan 2026 0001678248

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +7,139 +83% 15,745 05 Jan 2026 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Tax liability -2,080 -13% 13,665 05 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -7,139 -1.1% $0.000000 632,903 05 Jan 2026 Common Stock 7,139 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
F3 Derivative securities vest in equal tranches, 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029.
F4 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on January 5, 2026.